Recent developments in immunotoxin therapy

Current Opinion in Immunology

Volumn 6, Issue 5, 1994, Pages 707-714

  Ghetie, Maria Ana ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; RICIN A;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; HUMAN; MOUSE; NONHUMAN; NUDE MOUSE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANIMAL; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMAN; IMMUNOTOXINS; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS;

EID: 0028148350     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/0952-7915(94)90073-6     Document Type: Article

References (79)

1. Immunotoxins: Magic Bullets or Misguided Missiles
2. Immunotoxins Will Their Clinical Promise Be Fulfilled?
3. Immunotoxin Therapy for Cancer
4. Antibody Conjugates for the Treatment of Cancer
5. Targeted Kill: From Umbrellas to Monoclonal Antibodies
6. Recombinant Toxins as Novel Therapeutic Agents
7. Four Ricin Chain A-Based Immunotoxins Directed Against the Common Chronic Lymphocytic Leukemia Antigen: In Vitro Characterization
8. Three New Monoclonal Antibodies That Define a Unique Antigen Associated With Prolymphocytic Leukemia/Non-Hodgkin's Lymphoma and Are Effectively Internalized After Binding to the Cell Surface Antigen
9. Anti-CD6-Blocked Ricin An Anti-Pan TCell Immunotoxin
10. Cytotoxic Properties of a Ricin A Chain Immunotoxin Recognizing the Cluster-5A Antigen Associated With Human Small-Cell Lung Cancer
11. Potent Cytotoxic Action of the Immunotoxin SWA11-Ricin A Chain Against Human Small Cell Lung Cancer Cell Lines
12. An Anti-Mucin Immunotoxin BrE-3-Ricin A-Chain is Potently and Selectively Toxic to Human Small-Cell Lung Cancer
13. Potent Anti-CD5 Ricin-A Chain Immunoconjugates from Bacterially Produced Fab' and F(ab′)2
14. Combined Use of An Immunotoxin and Cyclosporine to Prevent Both Activated and Quiescent Peripheral Blood T-Cells from Producing Type-1 Human immunodeficiency Virus
15. A Bispecific Anti-CD22/Anti CD3Ricin A Chain Immunotoxin is Cytotoxic to Daudi Lymphoma Cells, but not T Cells in Vitro and Shows Both A Chain-Mediated and LAK-T Mediated Killing
16. Purification and Properties of Immunotoxins Containing One vs Two Deglycosylated Ricin A Chains
17. Recombinant Hybrid Toxin with Dual Enzymatic Activities. Potential Use in Preparing Highly Effective Immunotoxins
18. Cytotoxicity of a Recombinant Ricin-A-Chain Fusion Protein Containing a Proteolytical Cleavable Spacer Sequence
19. Expression of Immunoglobulin Heavy Chain Ricin A Chain Fusions in Mammalian Cells
20. In Vitro and In Vivo Properties of an Anti-CDS-Momordin Immunotoxin on Normal and Neoplastic T Lymphocytes
21. Characterization of Cytotoxic Activity of Saporin Anti-GP185/HER-2 Immunotoxins
22. Efficacy of Anti-CDS F(ab′)2 and Fab′ Immunoconjugates in Human Peripheral Blood Lymphocyte-Reconstituted Severe Com bined Immunodeficient Mice
23. Efficacy of an AntiCD5Ricin-A Chain Immunoconjugate in an Improved Human Peripheral Blood Lymphocyte-Reconstituted Severe Combined Immunodeficient Mouse Model
24. In Vitro Antibodies: Strategies for Production and Application
25. Humanized Immunotoxins
26. Cytotoxic Ribonucleases and Chimeras in Cancer Therapy
27. Cytotoxic Potential of Ribonuclease and Ribonuclease Hybrid Proteins
28. Cytoxic Ribonuclease Chimeras: Targeted Tumoricidal Activity In Vitro and In Vivo
29. Characterization of Single-Chain Antibody (sFv)Toxin Fusion Proteins Produced In Vitro in Rabbit Reticulocyte Lysate
30. Cytotoxic Onconase and Ribonuclease A Chimeras Comparison and In Vitro Characterization
31. The Aspergillus Toxin Restriction is a Suitable Cytotoxic Agent for Generation of Immunoconjugates with Monoclonal Antibodies Directed Against Human Carcinoma Cells
32. Biochemical, Cytotoxic and Pharmacokinetic Properties of an Immunotoxin Composed of a Mouse Monoclonal Antibody Fib75 and the Ribosome-Inactivating Protein Alpha-Sarcin from Aspergillus giganteus
33. Recent Advances With Monoclonal Antibody Drug Targeting for the Treatment of Human Cancer
34. Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs
35. Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibotics
36. Calicheamicin Gamma 1 and DNA: Molecular Recognition Process Responsible for Site-Specificity
37. Calicheamicin Gamma 1: An Antibiotic That Cleaves Double Stranded DNA Site Specifically
38. The Conjugation of Proteins with Polyethylene Glycol and Other Polymers
39. Chemical Engineering of the Monoclonal Antibody A7 by Polyethylene Glycol for Targeting Cancer Chemotherapy
40. Polyethylene Glycol Modification of the Monoclonal Antibody A7 Enhances Its Tumor Localization
41. Solubilization of Immunotoxins for Pharmaceutical Compositions Using Polymer Conjugation
42. Solubilization of Immunotoxins for Pharmaceutical Compositions Using Polymer Conjugation
43. Solubilization of Immunotoxins for Pharmaceutical Compositions Using Polymer Conjugation
44. Polyethylene Glycol-Modified Chimeric Toxin Composed of Transforming Growth Factor-Alpha and Pseudomonas Exotoxin
45. Activity of Immunotoxins Constructed with Modified Pseudomonas Exotoxin A Lacking the Cell Recognition Domain
46. Single-Chain Immunotoxin Fusions Between Anti-tac and Pseudomonas Exotoxin: Relative Importance of the Two Toxin Disulfide Bonds
47. BR96 sFv-PE40, a Potent Single-Chain Immunotoxin that Selectively Kills Carcinoma Cells
48. Processing of Pseudomonas Exotoxin by a Cellular Protease Results in the Generation of a 37,000-Da Toxin Fragment that is Translocated to the Cytosol
49. Immunotoxins Made With a Recombinant Form of Pseudomonas Exotozin A that Do Not Require Proteolysis for Activity
50. A Variant of Exotoxin A that Forms Potent and Specific Chemically-Conjugated Immunotoxins
51. Monovalent Immunotoxin Containing Truncated Form of Pseudomonas Exotoxin as Potent Antitumor Agent
52. Increased Cytotoxic Activity of Pseudomonas Exotozin and Two Chimeric Toxins Ending in KDEL
53. Affinity Purification and Characterization of Antitac (Fv)-c3-pe38kdel: A Highly Potent Cytotoxic Agent Specific to Cells Bearing IL-2 Receptors
54. Addition of an ER Retention Signal to the Ricin A Chain Increases the Cytotoxicity of the Holotoxin
55. Toxin Entry: How Reversible is the Secretory Pathway?
56. Anti-B4-Blocked Ricin Immunotoxin Shows Therapeutic Efficacy in Four Different SCID Mouse Tumor Models
57. Establishment of a Human t(4;11) Leukemia in Severe Combined Immunodeficient Mice and Successful Treatment Using Anti-CD19 (B43) Pokeweed Antiviral Protein Immunotoxin
58. In Vivo Efficacy of B43 (Anti-CD19)-Pokeweed Antiviral Protein Immunotoxin Against Human Pre-B Cell Acute Lymphoblastic Leukemia in Mice with Severe Combined immunodeficiency
59. anti-tumor Activity of a Blocked Ricin Immunotoxin with Specificity Against the Cluster-5a Antigen Associated with Human Small-Cell Lung Cancer
60. Pseudomonas Exotozin-Based Immunotoxins Containing the Antibody LL2 or LL2-Fab' Induce Regression of Subcutaneous Human B-Cell Lymphoma in Mice
61. Recombinant Immunotoxins Containing Anti-Tac(Fv) and Derivatives of Pseudomonas Exotozin Produce Complete Regression in Mice of an Interleukin-2 Receptor-Expressing Human Carcinoma
62. In Vitro and In Vivo Characterization of BF96 sFv-PE40
63. A Murine Model for Antibody-Directed Targeting of Vascular Endothelial Cells in Solid Tumors
64. Eradication of Large Solid Tumors in Mice with an Immunotoxin Directed Against Tumor Vasculature
65. Ricin A-Chain and Ricin A-Chain Immunotoxins Rapidly Damage Human Endothelial Cells Implications for Vascular Leak Syndrome
66. Successful Treatment of Disseminated Human Hodgkin's Disease in SCID Mice with Deglycosylated Ricin A Chain Immunotoxins
67. Effective Immunochemotherapy of Human t(4;11) Leukemia in Mice with Severe Com bined Immunodeficiency (SCID) Using, B43 (Anti-CD19)-Pokeweed Antiviral- Protein Immunotozin Plus Cyclophosphamide
68. Successful Treatment of Human Acute T-Cell Leukemia in SCID Mice Using the Anti-CD7-Deglycosylated Ricin A-Chain Immunotoxin DA7
69. Anti-CD19 Inhibits the Growth of Human B Cell Tumor Lines In Vitro and of Daudi Cells in SCID Mice by Inducing Reversible Cell Cycle Arrest
70. The Eradication of Minimal Disease in SCID Mice with Disseminated Daudi Lymphoma Using Chemotherapy and an Immunotoxin Cocktail
71. Serotherapy of B-Cell Neoplasms with Anti-B4 Blocked Ricin: A Phase-1 Trial of Daily Bolus Infusion
72. Anti-B4-Blocked Ricin: A Phase-1 Trial of 7-Day Continuous Infusion in Patients with B-Cell Neoplasms
73. Adjuvant Immunotoxin Therapy with Anti-B4Blocked Ricin After Autologous Bone Marrow Transplantation for Patients with BCel1 Non-Hodgkin's Lymphoma
74. A Phase I Study of an AntiCD22Deglycosylated Ricin A Chain Immunotoxin in the Treatment of BCell Lymphomas Resistant to Conventional Therapy
75. Annotation
76. Immunotoxin Therapy of Small-Cell Lung Cancer. N901-Blocked Ricin for Relapsed Small-Cell Lung Cancer
77. Combination Graft-Versus-Host Disease Prophylaxis Using Immunotoxin (Anti-CDS-RTA [Xomazyme CDS]) Plus Methotrexate and Cyclosporine or Prednisone After Unrelated Donor Marrow Transplantation
78. Phase 1/II Study of Murine Monoclonal Antibody-Ricin A Chain (XOMAZYME mel) Immunoconjugate Plus Cyclosporine A in Patients with Metastatic Melanoma
79. Response of Refractory Hodgkin's Disease to Monoclonal Anti-CD30 Immunotoxin